US court overturns Insulet's $452 million insulin-pump trade secret verdict against EOFlow

WASHINGTON - A U.S. appeals court on Thursday overturned a $452 million verdict that medical device maker Insulet won against Korean rival EOFlow for allegedly stealing trade secrets related to its insulin-pump technology.

The Washington-based U.S. Court of Appeals for the Federal Circuit reversed the verdict after finding that Insulet had waited too long to bring its lawsuit.

A federal jury in Massachusetts had determined in 2024 that EOFlow owed $452 million in damages for misappropriating Insulet trade secrets to create a competitor to Insulet's Omnipod, a wearable insulin pump for diabetes patients.

(Reporting by Blake Brittain in Washington)

Copyright Reuters or USA Today Network via Reuters Connect

This story was originally published May 28, 2026 at 10:38 AM.